InspireMD Inc (NSPR)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $30.13M
Last updated: Nov 17, 2026 at 11:05 AM ET
InspireMD Inc (NSPR) Earnings: Report Dates and Results
InspireMD (NSPR) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, InspireMD reported EPS of -$0.11, above the -$0.15 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NSPR has an expected report date of Mar 16, 2027.
NSPR Earnings Call
The latest NSPR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 34 quarters below that had an estimate, NSPR beat 26, missed 5 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $2.24M, down 11.1% from $2.52M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.11 | -$0.15 | -$0.16 - -$0.15 | +26.67% | Beat | N/A | 3 | 3 up, 0 down | Nov 12, 2026 | $2.24M |
| Jun 30, 2026 | -$0.17 | -$0.20 | -$0.21 - -$0.19 | +15.00% | Beat | N/A | 3 | 0 up, 2 down | Aug 14, 2026 | $1.77M |
| Mar 31, 2026 | -$0.16 | -$0.18 | -$0.19 - -$0.16 | +11.11% | Beat | N/A | 3 | 2 up, 0 down | May 4, 2026 | $3.40M |
| Dec 31, 2025 | -$0.14 | -$0.19 | -$0.22 - -$0.18 | +26.32% | Beat | N/A | 3 | 2 up, 0 down | Mar 18, 2026 | $3.15M |
| Sep 30, 2025 | -$0.17 | -$0.19 | -$0.22 - -$0.17 | +10.53% | Beat | N/A | 2 | 2 up, 0 down | Nov 4, 2025 | $2.52M |
| Jun 30, 2025 | -$0.26 | -$0.26 | -$0.28 - -$0.24 | 0.00% | In line | N/A | 2 | 0 up, 1 down | Aug 4, 2025 | $1.78M |
| Mar 31, 2025 | -$0.22 | -$0.20 | -$0.23 - -$0.17 | -10.00% | Miss | N/A | 2 | 1 up, 1 down | May 9, 2025 | $1.53M |
| Dec 31, 2024 | -$0.19 | -$0.20 | -$0.20 - -$0.19 | +5.00% | Beat | N/A | 2 | 1 up, 0 down | Mar 12, 2025 | $1.95M |
| Sep 30, 2024 | -$0.16 | -$0.20 | N/A | +20.00% | Beat | N/A | N/A | 0 up, 0 down | Nov 12, 2024 | $1.81M |
| Jun 30, 2024 | -$0.22 | -$0.19 | -$0.19 - -$0.19 | -15.79% | Miss | N/A | 1 | 0 up, 0 down | Aug 6, 2024 | $1.74M |
| Mar 31, 2024 | -$0.21 | -$0.15 | -$0.15 - -$0.15 | -40.00% | Miss | N/A | 1 | 0 up, 0 down | May 14, 2024 | $1.51M |
| Dec 31, 2023 | -$0.16 | -$0.19 | -$0.20 - -$0.19 | +15.79% | Beat | N/A | 2 | 0 up, 0 down | Mar 6, 2024 | $1.76M |
| Sep 30, 2023 | -$0.15 | -$0.15 | -$0.17 - -$0.14 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Nov 6, 2023 | $1.56M |
| Jun 30, 2023 | -$0.24 | -$0.30 | -$0.43 - -$0.17 | +20.00% | Beat | N/A | 2 | 0 up, 0 down | Aug 8, 2023 | $1.65M |
| Mar 31, 2023 | -$0.53 | -$0.68 | -$0.68 - -$0.68 | +22.06% | Beat | N/A | 1 | 0 up, 0 down | May 15, 2023 | $1.24M |
| Dec 31, 2022 | -$0.60 | -$0.84 | -$0.84 - -$0.84 | +28.57% | Beat | N/A | 1 | 0 up, 0 down | Mar 30, 2023 | $1.03M |
| Sep 30, 2022 | -$0.58 | -$0.73 | N/A | +20.55% | Beat | N/A | N/A | 0 up, 0 down | Nov 8, 2022 | $1.43M |
| Jun 30, 2022 | -$0.59 | -$0.73 | -$0.73 - -$0.73 | +19.18% | Beat | N/A | 1 | 0 up, 0 down | Aug 9, 2022 | $1.53M |
| Mar 31, 2022 | -$0.57 | -$0.80 | -$0.80 - -$0.80 | +28.75% | Beat | N/A | 1 | 0 up, 0 down | May 10, 2022 | $1.18M |
| Dec 31, 2021 | -$0.53 | -$0.78 | -$0.78 - -$0.78 | +32.05% | Beat | N/A | 1 | 0 up, 0 down | Mar 8, 2022 | $1.38M |
| Sep 30, 2021 | -$0.53 | -$0.82 | -$0.82 - -$0.82 | +35.37% | Beat | N/A | 1 | N/A | Nov 9, 2021 | $1.07M |
| Jun 30, 2021 | -$0.46 | -$9.45 | N/A | +95.13% | Beat | N/A | 1 | N/A | Aug 10, 2021 | $1.04M |
| Mar 31, 2021 | -$0.53 | -$0.60 | -$0.60 - -$0.60 | +11.67% | Beat | N/A | 1 | N/A | May 11, 2021 | $1.01M |
| Dec 31, 2020 | -$1.20 | -$0.97 | -$1.05 - -$0.90 | -23.71% | Miss | N/A | 2 | N/A | Mar 9, 2021 | $158000 |
| Sep 30, 2020 | -$0.90 | -$2.70 | -$4.20 - -$1.20 | +66.67% | Beat | N/A | 2 | N/A | Nov 9, 2020 | $980000 |
| Jun 30, 2020 | -$3.00 | -$5.25 | -$5.25 - -$5.25 | +42.86% | Beat | N/A | 1 | N/A | Aug 5, 2020 | $313000 |
| Mar 31, 2020 | -$6.45 | -$9.45 | -$9.45 - -$9.45 | +31.75% | Beat | N/A | 1 | N/A | May 12, 2020 | $1.03M |
| Dec 31, 2019 | -$8.55 | -$8.55 | -$8.55 - -$8.55 | 0.00% | In line | N/A | 1 | N/A | Mar 10, 2020 | $1.01M |
| Sep 30, 2019 | -$18.90 | -$20.25 | N/A | +6.67% | Beat | N/A | 1 | N/A | Nov 12, 2019 | $939000 |
| Jun 30, 2019 | -$23.85 | -$30.00 | N/A | +20.50% | Beat | N/A | 1 | N/A | Aug 6, 2019 | $1.35M |
| Mar 31, 2019 | -$57.30 | -$37.50 | N/A | -52.80% | Miss | N/A | N/A | N/A | May 14, 2019 | $415000 |
| Dec 31, 2018 | -$5.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 19, 2019 | $822000 |
| Sep 30, 2018 | -$2.50 | -$2.98 | N/A | +15.97% | Beat | N/A | N/A | N/A | Nov 6, 2018 | $769000 |
| Jun 30, 2018 | -$7.50 | -$148.75 | N/A | +94.96% | Beat | N/A | N/A | N/A | Aug 6, 2018 | $1.00M |
| Mar 31, 2018 | -$1.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2018 | $1.01M |
| Dec 31, 2017 | -$7.38 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 14, 2018 | $833000 |
| Sep 30, 2017 | -$4,987.50 | -$59,062.56 | N/A | +91.56% | Beat | N/A | N/A | N/A | Nov 7, 2017 | $718000 |
| Jun 30, 2017 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2017 | $640000 |
| Mar 31, 2017 | -$0.65 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2017 | $569000 |
| Dec 31, 2016 | -$1,531.72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 16, 2017 | $322000 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.79, after -$0.78 the year before. It was -$278,661.63 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.79 | N/A |
| Dec 31, 2024 | -$0.78 | N/A |
| Dec 31, 2023 | -$1.08 | N/A |
| Dec 31, 2022 | -$2.34 | N/A |
| Dec 31, 2021 | -$2.05 | N/A |
| Dec 31, 2020 | -$11.55 | N/A |
| Dec 31, 2019 | -$108.60 | N/A |
| Dec 31, 2018 | -$16.08 | N/A |
| Dec 31, 2017 | -$4,995.74 | N/A |
| Dec 31, 2016 | -$278,661.63 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,300 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,333 | 6 | |
| 2026Q2 | Jun 30, 2026 | 4,261 | 7 | |
| 2026Q1 | Mar 31, 2026 | 3,735 | 7 | |
| 2025Q3 | Sep 30, 2025 | 3,937 | 7 | |
| 2025Q2 | Jun 30, 2025 | 3,939 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,798 | 7 | |
| 2024Q4 | Dec 31, 2024 | 3,791 | 8 | |
| 2024Q3 | Sep 30, 2024 | 3,256 | 6 |
2026Q3 Earnings Call
Opening remarks
Alexandra Grossman LifeSci Advisors Thank you. During this call, management will make forward-looking statements, which are based upon management's current expectations, beliefs, and projections, many of which, by their nature, are inherently uncertain. These forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed in such forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K, quarterly report on Form 10-Q, any updates in its current reports on Form 8-K, as well as in InspireMD's press release that accompanies this call, particularly the cautionary statements made in it. During the call today, the company may also discuss certain non-GAAP financial measures. For a more detailed discussion of these non-GAAP financial measures and historical reconciliation to the most closely comparable GAAP measures, please refer to the company's earnings release. This call contains time-sensitive information that is accurate only as of today, November 12, 2026. Except as required by law, InspireMD disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Marvin Slosman, Chief Executive Officer. Marvin, please go ahead.
Marvin Slosman CEO Thank you, and good afternoon, everyone. The third quarter marked a turning point for InspireMD, and today I am pleased to discuss what we believe is one of the most significant milestones in the company's history. I first want to briefly address the financing announcement we issued today. As you saw in a separate press release issued this afternoon, we have announced a proposed underwritten equity public offering. This financing is intended to support the next phase of our growth, including the full commercialization of CGuard Prime in the U.S. and the broader execution of our strategic priorities. Given that the offering process is ongoing, there are SEC-imposed limitations on what can be discussed beyond the information included in today's announcement. Thus, we are not commenting on the potential size, pricing, timing, and other terms of the transaction during this call. We appreciate your understanding and look forward to providing additional information through the appropriate public disclosures as it becomes available. As I just mentioned, today I'm pleased to discuss what we believe is one of the most significant milestones in our company's history. With FDA approval of our CGuard Prime TransCarotid Stent System for TCAR procedures, we are returning to the U.S.
Frequently Asked Questions About NSPR
When is InspireMD's next earnings date?
InspireMD's next earnings report is expected for Mar 16, 2027.
Did NSPR beat earnings estimates last quarter?
Yes. InspireMD reported EPS of -$0.11 for the quarter ended Sep 30, 2026, above the -$0.15 estimate, a 26.67% surprise.
What EPS do analysts expect from NSPR next quarter?
The consensus EPS estimate for InspireMD for the quarter ending Dec 31, 2026 is -$0.13 from 5 analysts, with estimates from -$0.14 to -$0.12.
How often does NSPR beat earnings estimates?
InspireMD beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +10.58%.
NSPR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors